

Ref: 16/SE/LC/2026-27

Date: June 26, 2026

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,

**Head, Listing Compliance Department
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001

**Head, Listing Compliance Department
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400 051

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on June 26, 2026

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”), we wish to inform you that the Board of Directors of the Company, at its meeting held today, considered and approved following:

1. Based on the recommendations of the Nomination and Remuneration Committee, the Board has approved allotment of 1,475 (One Thousand Four Hundred and Seventy-Five) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employee of the Company, upon exercise of the Options vested under the Entero Employee Stock Option Plan 2023.

The details as required under the Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure A**.

2. In reference to our earlier intimation dated May 25, 2026, Ref. No.: 06/SE/LC/2026-27, it is further informed that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the revised tenure of reappointment of the Independent Directors to facilitate an effective succession planning process and ensure a smoother transition in the composition of the Board. Accordingly, the Board has approved the revised tenure for the re-appointment of Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Directors of the Company, subject to the approval of the shareholders at the ensuing Annual General Meeting. The tenure of Mr. Sujesh Vasudevan (DIN: 08240092) Non-Executive Independent Director remains unchanged.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, as amended, are enclosed as **Annexure-B**.

The above information will also be available on the website of the Company at www.enterohealthcare.com

The Board Meeting commenced at 01:00 p.m. (IST) and concluded at 02.45 p.m. (IST).

You are requested to take the same on record.

Yours faithfully,

For **Entero Healthcare Solutions Limited**

Sanu Kapoor
**Vice President- General Counsel, Company Secretary
& Compliance Officer**

Encl: as above

Annexure – A

Disclosures pursuant to Regulation 10 (c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021:

Sr. No.	Particulars	Disclosure Entero Employee Stock Option Plan 2023
1.	Company Name and Address of Registered Office	Entero Healthcare Solutions Limited Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Faridabad, Haryana, India, 121003.
2.	Name of the Stock Exchanges on which the Company's shares are listed	BSE Limited and National Stock Exchange of India Limited (NSE)
3.	Filing date of the statement referred in regulation 10(b) of the SEBI SBEBS Regulations, with Stock Exchange	BSE: 20/09/2024 NSE: 20/09/2024
4.	Filing Number, if any	BSE: 212075 NSE: 44198
5.	Title of the Scheme pursuant to which shares are issued	Entero Employee Stock Option Plan 2023
6.	Kind of security to be listed	Equity shares
7.	Par value of the shares	Rs. 10/-
8.	Date of issue of shares	June 26, 2026
9.	Number of shares issued	1,475
10.	Share Certificate No., if applicable	N.A.
11.	Distinctive number of shares, if applicable	4,35,21,598 to 4,35,23,072
12.	ISIN Number of the shares if issued in Demat	INE010601016
13.	Exercise price per share	Rs. 804 per equity share
14.	Premium per share	Rs. 794/- per equity share
15.	Total Issued shares after this issue	4,35,23,072
16.	Total Issued share capital after this issue	Rs. 43,52,30,720
17.	Details of any lock-in on the shares	The shares issued upon exercise shall be freely transferable and shall not be subject to any lock - in period restriction after such issue except as required under the Applicable Laws.
18.	Date of expiry of lock-in	Not Applicable
19.	Whether shares are identical in all respects to existing shares if not, when will they become identical?	All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if payable	Not Applicable

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003.
Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra.
Tel.: 022-26529100 / 69019100, CIN: L74999HR2018PLC072204

Annexure-B

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPD2/I/3762/2026:

Particulars	Mr. Rajesh Shashikant Dalal	Ms. Sandhya Gadkari Sharma
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Reappointment for 2 nd term of 4 (Four) consecutive years.	Reappointment for 2 nd term of 4 (Four) consecutive years.
Date of appointment/cessation (as applicable) and term of appointment	Date of Re-Appointment - August 25, 2026. Term of Re-appointment - 2 nd term of 4 (Four) consecutive years commencing from August 25, 2026, to August 24, 2030.	Date of Re-Appointment - August 25, 2026. Term of Re-appointment - 2 nd term of 4 (Four) consecutive years commencing from August 25, 2026, to August 24, 2030.
Brief Profile (in case of appointment)	Mr. Rajesh Shashikant Dalal is a healthcare leader and has 35 plus years of experience. He has been Managing Director of Johnson & Johnson India. Later he took Asia wide responsibility for M & A for Johnson & Johnson. After leaving Johnson & Johnson, he has worked closely with the Private Equity firms helping them evaluate healthcare opportunities and investing in them. He has also helped blue chip international companies like Philips Netherlands, Intuitive Surgicals USA, Alltech China etc. in formulating their India strategies. Rajesh is a mechanical Engineer from IIT Madras and MBA from Jamnalal Bajaj Institute Bombay.	Ms. Sandhya Gadkari Sharma has over Four decades of experience in Banking and Investment. She obtained her bachelor's degree of Commerce from the University of Bombay and a master's in management studies from University of Bombay. Previously, she was associated with Mahindra and Mahindra Limited and ICICI Bank Limited
Disclosure of relationships between Directors (in case of appointment of a Director)	Not Applicable	
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.	

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003.
Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra.
Tel.: 022-26529100 / 69019100, CIN: L74999HR2018PLC072204